Strong showing for Adagio's ADG20 in pre- and post-exposure settings for COVID-19

Shares of US biotech Adagio Therapeutics (Nasdaq: ADGI) shot up more than 53% to $5.90 by late morning trading today, after it reported that the primary endpoints were met with statistical significance for all three indications in the company’s ongoing global Phase II/III clinical trials evaluating its investigational drug adintrevimab (ADG20) as a pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19.

EVADE and STAMP were primarily conducted during a time when pre-Omicron SARS-CoV-2 variants were dominant. Following the emergence of the Omicron variant, in a pre-specified exploratory analysis in a subset of the pre-exposure cohort, a clinically meaningful reduction in cases of symptomatic COVID-19 was observed with adintrevimab compared to placebo. Across both trials, a single intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo.

Regulatory filing discussions planned